| Name | Title | Contact Details |
|---|
PrinterPrezz`s mission is to bring more ideas for innovative medical devices to market faster, connecting medicine and manufacturing to become the first Medifacturing™ company in the world. By developing advanced medical devices using processes that combine expertise in 3D printing, orthopaedics, semiconductor and nanotechnologies, PrinterPrezz`s ultimate goal is to provide medical solutions that enable people to enjoy active lives longer. PrinterPrezz`s ecosystem aims to solve challenges for various parts of the medical innovation value chain by providing prototyping, development, and manufacturing services to create life-enhancing medical devices. Committed to ongoing compliance with ISO13485:2016 and all relevant regulatory requirements, PrinterPrezz provides customers with access to a variety of 3D printing machines, 3D manipulation software, and 3D scanners as well as advanced manufacturing processes, and surgeon education programs. Medical solutions created by PrinterPrezz are designed to enable more people to live happier and more gratifying lives.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.
Chesapeake is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.
Osiris Therapeutics, Inc. is a leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. Osiris’ stem cell products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent pathological scar formation. In Biosurgery, we harness the ability of cells and novel constructs to promote the body`s natural healing. The goals are to improve surgical outcomes and offer better treatment options for patients and physicians. We like a challenge, so the focus is in areas where we believe we can have a significant impact. Difficult indications and challenging cases are targeted. Osiris has been studying tissue engineering since the beginning, and its dedicated team conducted groundbreaking research in the field. The work in bone led to the development of the successful product Osteocel, now owned by NuVasive Inc. Now, application of these technologies is being expanded beyond bone, to soft tissues, such as cartilage and tendon, and also wound healing.